19 completed, 4 recruiting, 4 unknown, 3 terminated. 10 Not applicable, 9 Phase 2, 7 Phase 1, 2 Phase 3.
Follow Choroideremia: new trials by email Literature Review of Choroideremia trials Research Report on Choroideremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) RTx-015 - Retinitis Pigmentosa, Choroideremia | Phase 1 | Active not recruiting | Ray Therapeutics, Inc. | 10 | 2024-08-27 | 2026-02-20 |
| Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration Retinitis Pigmentosa, Choroideremia | Recruiting | Ray Therapeutics, Inc. | 120 | 2024-04-05 | 2025-01-08 | |
| HYPER MIND - Hyperoxia Effects on Cerebral Hemodynamics Normobaric Hyperoxic Stimulus (NBHO) - Hyperoxemia, Cerebrovascular Circulation | Not applicable | Recruiting | Erasme University Hospital | 80 | 2024-01-01 | 2026-01-29 |
| The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study Vitamin A palmitate - Choroideremia | Not applicable | Withdrawn | Duke University | 2023-05-01 | 2023-06-29 | |
| Effects of Aerobic Exercise on the Cerebral Arterial System, Cognitive, and Motor Function in Post-stroke Patients. treadmill exercise, Cycle ergometer exercise - Stroke | Not applicable | Unknown | The Hong Kong Polytechnic University | 120 | 2023-02-10 | 2024-02-28 |
| A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) KIO-301 - Retinitis Pigmentosa, Choroideremia | Phase 1 / Phase 2 | Completed | Kiora Pharmaceuticals, Inc. | 32 | 2022-11-10 | 2026-05-04 |
| Longitudinal Study of a Bionic Eye Retinitis Pigmentosa, Choroideremia | Enrolling by invitation | Center for Eye Research Australia | 7 | 2021-12-09 | 2024-08-23 | |
| Structural and Functional Characterization of Rare Ocular Diseases Retinitis Pigmentosa, Stargardt Disease 1 | Unknown | Barcelona Macula Foundation | 50 | 2021-11-24 | 2022-03-15 | |
| A Study to Assess Choroideremia (CHM) Health Outcomes No Intervention - Choroideremia | Completed | Biogen | 46 | 2020-12-15 | 2021-10-14 | |
| Natural Disease Progression in Participants With Choroideremia No Intervention - Choroideremia | Completed | Biogen | 1178 | 2020-08-26 | 2021-09-08 | |
| Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia 4D-110 - Choroideremia | Phase 1 | Active not recruiting | 4D Molecular Therapeutics | 13 | 2020-06-02 | 2025-05-22 |
| Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS RETINA IMPLANT Alpha AMS - Retinal Degeneration, Inherited Retinal Dystrophy Primarily Involving Sensory Retina | Not applicable | Terminated | Retina Implant AG | 2 | 2018-09-04 | 2019-04-19 |
| Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa BIIB111, BIIB112 - Choroideremia, X-Linked Retinitis Pigmentosa | Phase 3 | Completed | NightstaRx Ltd, a Biogen Company | 277 | 2018-06-04 | 2026-07-06 |
| Study of a Suprachoroidal Retinal Prosthesis 44Ch Bionic Eye Device - Retinitis Pigmentosa, Choroideremia | Not applicable | Completed | Mobius Medical Pty Ltd. | 4 | 2018-02-13 | 2021-08-16 |
| Efficacy and Safety of BIIB111 for the Treatment of Choroideremia BIIB111 - Choroideremia | Phase 3 | Completed | Biogen | 169 | 2017-12-11 | 2023-12-07 |
| A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 BIIB111 - Choroideremia | Phase 2 | Completed | Biogen | 66 | 2017-11-29 | 2024-02-23 |
| Invasive Versus Non Invasive Measurement of Intracranial Pressure in Brain Injury Trial (IMPRESSIT) transcranial Doppler - Intracranial Hypertension | Unknown | Università degli Studi di Brescia | 490 | 2017-07-01 | 2020-07-01 | |
| "Natural History" Study of Choroideremia Observation - Choroideremia | Terminated | 4D Molecular Therapeutics | 57 | 2016-12-01 | 2022-01-06 | |
| REP1 Gene Replacement Therapy for Choroideremia AAV-mediated REP1 gene replacement - Choroideremia | Phase 2 | Completed | University of Oxford | 30 | 2016-08-16 | 2021-08-05 |
| Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy Intelligent Retinal Implant System - Retinitis Pigmentosa, Cone Rod Dystrophy | Not applicable | Completed | Science Corporation | 10 | 2016-01-01 | 2019-05-29 |
Showing 20 of 34. Sign in to see all of them.
Retinitis Pigmentosa (14) · Cone-Rod Dystrophies (5) · Retinal Degeneration (4) · Stargardt Disease (3) · Retinal Dystrophies (2) · Vitelliform Macular Dystrophy (2) · Abetalipoproteinemia (1) · Achromatopsia 3 (1) · Alcoholism (1) · Bardet-Biedl Syndrome (1) · Charcot-Marie-Tooth Disease (1) · Color Vision Defects (1) · Cone Dystrophy (1) · Critical Illness (1)
Choroid Diseases (34) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (34) · Eye Diseases (34) · Genetic Diseases, Inborn (34) · Genetic Diseases, X-Linked (34) · Uveal Diseases (34) · Eye Diseases, Hereditary (33) · Retinal Diseases (15) · Retinal Dystrophies (13) · Retinal Degeneration (12) · Nervous System Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Disease Attributes (3)
Cotoretigene Toliparvovec (1) · Genetic Therapy (1) · Observation (1) · Simvastatin (1) · Transcranial Magnetic Stimulation (1) · Ultrasonography, Doppler, Transcranial (1) · retinol palmitate (1)
Biogen (4) · 4D Molecular Therapeutics (2) · Center for Eye Research Australia (2) · NightstaRx Ltd, a Biogen Company (2) · Ray Therapeutics, Inc. (2) · Science Corporation (2) · University of Alberta (2) · University of Oxford (2) · Barcelona Macula Foundation (1) · Byron Lam (1) · Central Institute of Psychiatry, Ranchi, India (1) · Duke University (1) · Erasme University Hospital (1) · Foundation Fighting Blindness (1) · Intelligent Medical Implants GmbH (1)
United States (16) · France (7) · Germany (7) · Canada (6) · United Kingdom (6) · Australia (4) · Denmark (3) · Finland (3) · Netherlands (3) · Austria (2) · Brazil (2) · Spain (2) · Belgium (1) · Hong Kong (1) · India (1)
Ian M MacDonald, MD, CM (2) · Robert E MacLaren, MB ChB DPhil (2) · Schonmei Lee, MD (2) · Andrew J Lotery, MD (1) · Andrew R Webster, MD (1) · Anthony Burkitt, PhD (1) · Fabio Silvio Taccone, MD, PhD (1) · Frank A Rasulo, MD (1) · Gisbert Richard, Prof. (1) · Graeme C Black, MB BCh DPhil (1) · Jessica IW Morgan, PhD (1) · Kaushik Mandal, MD (1) · Len W Seymour, PhD (1)
PMID 30194931, PMID 11153967, PMID 11468137, PMID 12637048, PMID 16129568, PMID 16905439, PMID 17113598, PMID 1992832, PMID 24439297, PMID 25190651, PMID 25205858, PMID 25521292, PMID 25744334, PMID 2597811, PMID 27170910, PMID 27403996, PMID 27820636, PMID 28660276, PMID 28793152, PMID 31269854, PMID 31465092, PMID 34383875, PMID 34581770, PMID 35428353, PMID 35696133, PMID 35714735, PMID 36066322, PMID 38970425, PMID 40174607, PMID 41981307, PMID 42157690
2017 (2), 2009 (1), 2015 (1), R24EY019861 (1)